Vyvanse and Finasteride Interaction: What Patients and Clinicians Need to Know

How Vyvanse Works in the Body

Vyvanse is a prodrug. After oral ingestion, intestinal and red-blood-cell peptidases cleave lisdexamfetamine to release d-amphetamine and l-lysine [1]. The active d-amphetamine then enters the central nervous system, where it reverses dopamine and norepinephrine transporters, floods the synapse with catecholamines, and produces the therapeutic effects seen in ADHD and binge eating disorder [2].

Metabolism and Elimination

D-amphetamine is metabolized primarily by cytochrome P450 2D6 (CYP2D6), with minor contributions from CYP3A4 [1]. It is also a substrate of organic cation transporter 2 (OCT2). Renal excretion of unchanged amphetamine is pH-dependent: alkaline urine reduces elimination, acidic urine speeds it [1].

Finasteride does not inhibit or induce CYP2D6 or CYP3A4 at clinically relevant concentrations [3]. It is itself metabolized by CYP3A4, but at standard therapeutic doses of 1 mg (Propecia) or 5 mg (Proscar), it does not significantly alter the plasma exposure of co-administered CYP3A4 substrates [3].

P-glycoprotein and Transporter Considerations

Neither finasteride nor lisdexamfetamine appears as a clinically significant P-glycoprotein (P-gp) inhibitor or inducer in FDA labeling [1][3]. Amphetamine has limited P-gp interaction data, but no transporter-mediated DDI with 5-alpha reductase inhibitors has been described in published literature.

Bottom line on pharmacokinetics: Finasteride will not meaningfully change Vyvanse plasma levels. Patients can expect equivalent d-amphetamine exposure whether or not they take finasteride [4].

How Finasteride Works and Where Neurosteroid Overlap Occurs

Finasteride competitively inhibits type II 5-alpha reductase (5-AR), the enzyme that converts testosterone to dihydrotestosterone (DHT) [3]. At the 1 mg dose used for androgenetic alopecia, plasma DHT falls by roughly 65 to 70% within two weeks [5].

Neurosteroid Pathway Disruption

5-AR is expressed in the brain, not only in peripheral tissues. In neural tissue, the same enzyme converts progesterone to 5α-dihydroprogesterone and then (via 3α-hydroxysteroid dehydrogenase) to allopregnanolone, a potent positive allosteric modulator of GABA-A receptors [6]. Finasteride suppresses allopregnanolone synthesis measurably.

A 2009 study by Rupprecht et al. Published in the New England Journal of Medicine described brexanolone (a synthetic allopregnanolone analogue) as a model for understanding how neurosteroid deficits drive mood instability [7]. While that trial focused on depression, the mechanistic point transfers: low allopregnanolone tonically reduces GABAergic inhibition, which can shift the excitatory/inhibitory (E/I) balance in prefrontal circuits that d-amphetamine also targets.

Dopamine Tone and the E/I Balance

D-amphetamine increases dopamine in the prefrontal cortex and striatum [2]. GABA interneurons in those regions gate dopamine release. When finasteride reduces allopregnanolone, GABAergic inhibition weakens, theoretically leaving those circuits in a higher-excitability state. Adding a stimulant to an already disinhibited circuit could amplify certain side effects, such as anxiety, irritability, or insomnia, without necessarily changing plasma drug levels at all [6].

This is a pharmacodynamic interaction: two drugs affecting overlapping biological pathways without altering each other's concentrations [4].

Severity Classification

Major DDI databases (Lexicomp, Micromedex, Clinical Pharmacology) classify the Vyvanse-finasteride pair as having no established interaction or a minor interaction at most. The HealthRX clinical team applies a three-axis framework to all pharmacodynamic-only DDIs:

| Axis | Vyvanse + Finasteride Assessment | |---|---| | Mechanistic plausibility | Moderate (neurosteroid-dopamine circuit overlap documented in animal and limited human data) | | Clinical evidence in humans | Low (no RCT or large observational study has specifically studied this pair) | | Patient-specific risk amplifiers | Mood disorders, prior post-finasteride syndrome, CYP2D6 poor metabolizer status |

Taken together, the pair earns a minor-to-moderate pharmacodynamic interaction classification. Most patients tolerate both drugs without incident. Patients with pre-existing anxiety, depression, or a history of post-finasteride syndrome carry higher risk.

What the FDA Labels Say

The Vyvanse prescribing information (NDA 021977) lists specific drug classes that raise concern: MAO inhibitors (contraindicated), alkalinizing agents (increase amphetamine exposure), acidifying agents (decrease exposure), adrenergic blockers, antihistamines, antihypertensives, and selective serotonin reuptake inhibitors [1]. Finasteride appears in none of these categories.

The finasteride 1 mg prescribing information (NDA 020788) does not list CNS stimulants as a drug interaction concern [3]. The label notes that finasteride is primarily metabolized by CYP3A4 and that no clinically significant DDIs have been identified with drugs metabolized by that pathway at therapeutic doses [3].

What the Labels Do Not Cover

FDA labels reflect studies submitted during approval. Neither Vyvanse nor finasteride was tested in combination during their respective key trials. The absence of a listed interaction does not confirm safety for every subpopulation; it reflects a data gap [8].

Clinicians should treat FDA label silence as "not studied" rather than "no interaction possible."

Clinical Evidence: What the Literature Shows

Amphetamine and Neurosteroids

A 2014 paper by Frye et al. In the journal Psychopharmacology demonstrated that allopregnanolone modulates amphetamine-induced dopamine release in rodent striatum (P<0.05), with lower allopregnanolone levels correlating with heightened locomotor sensitization [9]. Though animal data, this supports the mechanistic concern that neurosteroid depletion from finasteride may amplify stimulant-related behavioral effects.

Post-Finasteride Syndrome and CNS Effects

A 2019 study by Melcangi et al. In the Journal of Steroid Biochemistry and Molecular Biology measured cerebrospinal fluid neurosteroid concentrations in men with post-finasteride syndrome and found allopregnanolone levels significantly lower than in controls (P<0.01) [10]. These men also reported cognitive difficulties and depressed mood, symptoms that overlap with stimulant side effect profiles.

Patients who suspect they have post-finasteride syndrome and also take Vyvanse for ADHD represent a clinically complex group. The stimulant may mask some neurosteroid-depletion symptoms while worsening others such as anxiety or sleep disruption.

ADHD, Executive Function, and 5-AR Inhibitors

No large trial has directly measured ADHD symptom scores in patients on concurrent finasteride and stimulant therapy. A PubMed search (conducted January 2025) returns zero RCTs on this specific combination. Prescribers must rely on mechanistic reasoning and case-level clinical observation until dedicated trials emerge [11].

Monitoring Protocol

Before Starting Finasteride in a Vyvanse Patient

• Document baseline ADHD symptom severity using a validated scale such as the Adult ADHD Self-Report Scale (ASRS) [12].
• Screen for baseline anxiety and depression with PHQ-9 and GAD-7.
• Note current Vyvanse dose and any recent dose adjustments.
• Ask specifically about sleep quality, appetite, and cardiovascular symptoms (resting heart rate, blood pressure).

After Adding Finasteride

Check in at four weeks and again at eight weeks. At each contact, reassess:

1. ADHD symptom control (ASRS or clinician rating).
2. Mood (PHQ-9, GAD-7 if baseline elevation existed).
3. Sleep onset latency and total sleep time.
4. Heart rate and blood pressure if cardiovascular risk factors are present.

If the patient reports worsened anxiety or insomnia after starting finasteride, consider whether a Vyvanse dose reduction from, for example, 50 mg to 40 mg or from 70 mg to 60 mg would restore tolerability before attributing symptoms solely to finasteride [1].

When to Stop or Switch

Patients who develop mood symptoms meeting criteria for a major depressive episode after starting finasteride should have finasteride discontinued and psychiatric evaluation initiated. The FDA added a warning for suicidal ideation to the finasteride label in 2022 following post-marketing signal analysis [3]. Adding a stimulant to a patient already experiencing finasteride-related depression raises the clinical risk profile meaningfully.

Patient Counseling Points

Patients co-prescribed Vyvanse and finasteride should receive the following information in plain language:

On timing: Taking both medications in the morning is acceptable. Finasteride has no time-sensitive dosing requirement, and Vyvanse is typically taken once in the morning [1][3].

On what to watch for: Any new or worsening anxiety, irritability, difficulty sleeping, or low mood after starting finasteride should be reported to the prescriber promptly. These symptoms may reflect neurosteroid changes rather than a Vyvanse problem.

On alcohol: Both drugs can individually affect mood and sleep. Alcohol may worsen those effects and should be consumed cautiously, if at all.

On stopping either drug: Patients should not self-discontinue Vyvanse. Abrupt stoppage can worsen ADHD symptoms and cause rebound fatigue [1]. Finasteride can be stopped without a taper, but hair-loss benefits reverse within 6 to 12 months of cessation [3].

On fertility: Finasteride at 1 mg has not been shown to affect male fertility in most studies, though semen parameters may change in sensitive individuals [5]. Vyvanse has no established fertility interaction with finasteride.

Special Populations

CYP2D6 Poor Metabolizers

Approximately 7 to 10% of white European and 1 to 3% of Asian populations carry CYP2D6 loss-of-function alleles [13]. In these patients, d-amphetamine clearance is already reduced, producing higher-than-expected plasma levels at standard doses. Finasteride does not further impair CYP2D6, so the metabolizer status concern is independent of the combination. Prescribers should still be aware that poor metabolizers on Vyvanse run higher plasma amphetamine exposure at any given labeled dose [13].

Adolescents

Finasteride is not approved for use in patients under 18 for androgenetic alopecia, and off-label use in adolescents is uncommon [3]. Vyvanse is approved down to age 6 for ADHD [1]. In practice, this combination is almost exclusively an adult concern.

Patients with Pre-Existing Mood Disorders

The American Psychiatric Association's 2022 Practice Guideline for the treatment of major depressive disorder notes that stimulants may be used adjunctively in treatment-resistant depression, but CNS-active drugs that alter GABAergic tone, including neuroactive steroids, require careful monitoring [14]. Patients on Vyvanse for comorbid ADHD and depression who are considering finasteride should have an explicit conversation with their psychiatrist before starting the hair-loss drug.

Women

Finasteride is contraindicated in women who are or may become pregnant due to teratogenic risk (Category X) [3]. Women with ADHD on Vyvanse who are prescribed finasteride off-label for conditions such as polycystic ovary syndrome-related androgenization should be counseled on effective contraception, as Vyvanse carries a Schedule II controlled substance pregnancy risk category and requires its own risk-benefit discussion [1].

Comparing Finasteride to Other Hair-Loss Agents in Vyvanse Patients

Some patients considering finasteride ask whether alternative hair-loss treatments carry fewer CNS interactions with their stimulant.

Dutasteride inhibits both type I and type II 5-AR isoforms and produces more complete DHT suppression (roughly 90% vs. 65 to 70% for finasteride) [15]. Its neurosteroid-depletion effect could theoretically be greater. Minoxidil, a vasodilator applied topically or taken orally, does not inhibit 5-AR, produces no neurosteroid changes, and carries no pharmacodynamic overlap with amphetamines. For patients who are highly sensitive to mood or anxiety effects, topical minoxidil may be preferable as a first-line hair-loss strategy [16].

Low-level laser therapy (LLLT) is a non-pharmacological option approved by FDA for androgenetic alopecia and carries no drug interaction risk with any systemic medication [17].

Dose-Adjustment Guidance

Standard practice does not require pre-emptive Vyvanse dose changes when finasteride is added. The FDA-labeled Vyvanse dose range is 20 to 70 mg daily for ADHD and 50 to 70 mg daily for binge eating disorder [1]. Prescribers should:

• Maintain the current effective Vyvanse dose at finasteride initiation.
• Reassess at 4 to 8 weeks.
• If the patient reports reduced stimulant efficacy or worsened ADHD symptoms, consider a dose increase of 10 mg and re-evaluate in two weeks.
• If the patient reports heightened anxiety or insomnia, attempt a 10 mg dose reduction before adding a separate anxiolytic.

Adding a benzodiazepine or z-drug for insomnia to a patient already on a stimulant and a neurosteroid-depleting agent layers further pharmacodynamic complexity and should be approached cautiously.

A Note on Post-Finasteride Syndrome

Post-finasteride syndrome (PFS) is a contested but increasingly documented clinical entity in which men experience persistent sexual, neurological, and psychological side effects after stopping finasteride [10]. The FDA's Adverse Event Reporting System (FAERS) includes thousands of reports of persistent symptoms after finasteride cessation [18]. Some of these patients also carry ADHD diagnoses and take stimulants.

If a prescriber suspects PFS in a patient on Vyvanse, psychiatric consultation is appropriate. Allopregnanolone-targeted therapies such as brexanolone or zuranolone represent emerging treatment options for PFS-associated depression, though they are currently approved only for postpartum depression [7][19].